• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Pharmacogenetics and the future of medical practice.药物遗传学与医学实践的未来。
Br J Clin Pharmacol. 2002 Aug;54(2):221-30. doi: 10.1046/j.1365-2125.2002.01630.x.
2
Pharmacogenetics and the future of medical practice.药物遗传学与医学实践的未来。
J Mol Med (Berl). 2003 Mar;81(3):141-53. doi: 10.1007/s00109-002-0416-5. Epub 2003 Mar 25.
3
Pharmacogenetics in drug regulation: promise, potential and pitfalls.药物监管中的药物遗传学:前景、潜力与陷阱
Philos Trans R Soc Lond B Biol Sci. 2005 Aug 29;360(1460):1617-38. doi: 10.1098/rstb.2005.1693.
4
Tailor-made pharmacotherapy: future developments and ethical challenges in the field of pharmacogenomics.量身定制的药物治疗:药物基因组学领域的未来发展与伦理挑战
Bioethics. 2004 Aug;18(4):303-21. doi: 10.1111/j.1467-8519.2004.00399.x.
5
Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview.药物发现与开发中的药物遗传学和药物基因组学:综述
Clin Chem Lab Med. 2003 Apr;41(4):398-410. doi: 10.1515/CCLM.2003.063.
6
Tailored medicine: whom will it fit? The ethics of patient and disease stratification.精准医疗:谁将从中受益?患者与疾病分层的伦理问题。
Bioethics. 2004 Aug;18(4):322-42. doi: 10.1111/j.1467-8519.2004.00400.x.
7
Pharmacogenetics in drug discovery and development: a translational perspective.药物发现与开发中的药物遗传学:一个转化医学视角
Nat Rev Drug Discov. 2008 Oct;7(10):807-17. doi: 10.1038/nrd2593. Epub 2008 Sep 19.
8
Pharmacogenetics: from discovery to patient care.药物遗传学:从发现到患者护理。
Am J Health Syst Pharm. 2009 Apr 1;66(7):625-37. doi: 10.2146/ajhp080170.
9
Asthma pharmacogenomics.哮喘药物基因组学
Immunol Allergy Clin North Am. 2005 Nov;25(4):723-42. doi: 10.1016/j.iac.2005.09.004.
10
Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications.性功能障碍的药物遗传学和药物基因组学:现状、差距和潜在应用。
Pharmacogenomics. 2009 Oct;10(10):1625-44. doi: 10.2217/pgs.09.104.

引用本文的文献

1
Pharmacogenetics in critical care: association between CYP3A5 rs776746 A/G genotype and acetaminophen response in sepsis and septic shock.重症监护中的药物遗传学:CYP3A5 rs776746 A/G 基因型与脓毒症和感染性休克中对乙酰氨基酚反应的关联。
BMC Anesthesiol. 2023 Feb 16;23(1):55. doi: 10.1186/s12871-023-02018-y.
2
The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.CYP2D6 基因全长编码区多态性与中国云南省间日疟复发率增高的相关性。
Malar J. 2021 Mar 20;20(1):160. doi: 10.1186/s12936-021-03685-3.
3
Dyskinesias and levodopa therapy: why wait?运动障碍与左旋多巴治疗:为何要等待?
J Neural Transm (Vienna). 2018 Aug;125(8):1119-1130. doi: 10.1007/s00702-018-1856-6. Epub 2018 Feb 10.
4
Perspective on the Genetic Response to Antiparasitics: A Review Article.抗寄生虫药物遗传反应的视角:一篇综述文章
Iran J Parasitol. 2017 Oct-Dec;12(4):470-481.
5
Optimization of Antidepressant use with Pharmacogenetic Strategies.采用药物遗传学策略优化抗抑郁药的使用
Curr Genomics. 2017 Oct;18(5):442-449. doi: 10.2174/1389202918666170426164940.
6
CYP2D6 allele distribution in Macedonians, Albanians and Romanies in the Republic of Macedonia.马其顿共和国马其顿人、阿尔巴尼亚人和罗姆人中CYP2D6等位基因的分布情况。
Balkan J Med Genet. 2016 Jul 9;18(2):49-58. doi: 10.1515/bjmg-2015-0086. eCollection 2015 Dec 1.
7
Adding Genetic Testing to Evidence-Based Guidelines to Determine the Safest and Most Effective Chronic Pain Treatment for Injured Workers.将基因检测纳入循证指南,以确定针对受伤工人的最安全、最有效的慢性疼痛治疗方法。
Int J Biomed Sci. 2015 Dec;11(4):157-65.
8
Testing patients to allow tailored drug treatment.对患者进行检测以实现个性化药物治疗。
BMJ. 2005 Feb 12;330(7487):352. doi: 10.1136/bmj.330.7487.352.
9
What is the impact of the ACE gene insertion/deletion (I/D) polymorphism on the clinical effectiveness and adverse events of ACE inhibitors?--Protocol of a systematic review.血管紧张素转换酶(ACE)基因插入/缺失(I/D)多态性对ACE抑制剂临床疗效及不良事件有何影响?——一项系统评价方案
BMC Med Genet. 2004 Sep 10;5:23. doi: 10.1186/1471-2350-5-23.

本文引用的文献

1
Proposed international guidelines on ethical issues in medical genetics and genetic services (part I).医学遗传学与遗传服务伦理问题国际准则建议(第一部分)
Rev Derecho Genoma Hum. 1998 Jan-Jun(8):219-23.
2
Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents.DNA修复基因MGMT的失活与胶质瘤对烷化剂的临床反应
N Engl J Med. 2000 Nov 9;343(19):1350-4. doi: 10.1056/NEJM200011093431901.
3
Genetic factors in aminoglycoside toxicity.
Ann N Y Acad Sci. 1999 Nov 28;884:99-109. doi: 10.1111/j.1749-6632.1999.tb08639.x.
4
Pharmacogenetics and future drug development and delivery.药物遗传学与未来药物研发及给药
Lancet. 2000 Apr 15;355(9212):1358-61. doi: 10.1016/S0140-6736(00)02126-7.
5
Pharmacogenomics: translating functional genomics into rational therapeutics.药物基因组学:将功能基因组学转化为合理的治疗方法。
Science. 1999 Oct 15;286(5439):487-91. doi: 10.1126/science.286.5439.487.
6
Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment.ALOX5启动子基因型与抗哮喘治疗反应之间的药物遗传学关联。
Nat Genet. 1999 Jun;22(2):168-70. doi: 10.1038/9680.
7
Not quite pharmacogenomics.不完全是药物基因组学。
Nat Biotechnol. 1998 Dec;16(13):1295. doi: 10.1038/4244.
8
Polymorphisms of the 5' leader cistron of the human beta2-adrenergic receptor regulate receptor expression.人类β2-肾上腺素能受体5'前导顺反子的多态性调节受体表达。
J Clin Invest. 1998 Dec 1;102(11):1927-32. doi: 10.1172/JCI4862.
9
Beta2-adrenoceptor polymorphisms are in linkage disequilibrium, but are not associated with asthma in an adult population.β2肾上腺素能受体基因多态性处于连锁不平衡状态,但在成年人群中与哮喘无关。
Clin Exp Allergy. 1998 Apr;28(4):442-8. doi: 10.1046/j.1365-2222.1998.00245.x.
10
Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing.有喘息病史和无喘息病史儿童的β2肾上腺素能受体基因多态性与沙丁胺醇反应之间的关联
J Clin Invest. 1997 Dec 15;100(12):3184-8. doi: 10.1172/JCI119874.

药物遗传学与医学实践的未来。

Pharmacogenetics and the future of medical practice.

作者信息

Lindpaintner Klaus

机构信息

Roche Genetics, F. Hoffmann-La Roche Ltd, Basel, Switzerland.

出版信息

Br J Clin Pharmacol. 2002 Aug;54(2):221-30. doi: 10.1046/j.1365-2125.2002.01630.x.

DOI:10.1046/j.1365-2125.2002.01630.x
PMID:12207645
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1874402/
Abstract

Pharmacogenetic approaches are widely expected to bring about a "revolution" in medicine. While the application of molecular genetic approaches to disease research will provide us with new opportunities for progressively more targeted and, hopefully, more effective treatments, these developments will be evolutionary in nature and will, for their realization, still require the painstaking process that discovering and developing a new drug entails. It is also quintessential for the realization of these promises that we support a more rational understanding and more realistic expectations in the public at large through dialogue and information.

摘要

药物遗传学方法被广泛认为将给医学带来一场“革命”。虽然将分子遗传学方法应用于疾病研究将为我们提供新的机会,以实现更具针对性、有望更有效的治疗,但这些进展本质上是渐进式的,而且要实现这些进展,仍需要经历发现和开发一种新药所必需的艰苦过程。同样至关重要的是,为了实现这些承诺,我们要通过对话和信息传播,促使广大公众形成更理性的认识和更现实的期望。